NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation (NMTC): 7 pipeline candidates · 1 upcoming catalyst · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.4 months
D/E 0.46 · 0% dilution
Lead: Approved
7 candidates
1 upcoming, next in ~1992d
1 buy · 5 sells (180d)
A transparent, data-derived signal for NeuroOne Medical Technologies Corporationacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$27.9M
Cash
$2.8M
Quarterly Burn
$1.3M
Runway
9.4 mo
Revenue
$2.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| basivertebral nerve ablation system | Preclinical |
| drug delivery system | Preclinical |
| evo cortical electrode | Approved |
| evo seeg electrode | Approved |
| neurological drug delivery seeg electrode | Preclinical |
| onerf ablation system | Approved |
| spinal cord stimulation system | Preclinical |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$16
| Holder | Shares | Value |
|---|---|---|
| sbi securities co., ltd. | 20 | $16 |
Frequently asked questions
How many drug candidates are in NeuroOne Medical Technologies Corporation's pipeline?
NeuroOne Medical Technologies Corporation (NMTC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NeuroOne Medical Technologies Corporation's lead drug candidate?
NeuroOne Medical Technologies Corporation's most advanced tracked candidate is basivertebral nerve ablation system (Preclinical) for Chronic low back pain.
What is NeuroOne Medical Technologies Corporation's next catalyst?
NeuroOne Medical Technologies Corporation's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy " — expected December 1, 2031.
What is NeuroOne Medical Technologies Corporation's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NeuroOne Medical Technologies Corporation has approximately 9.4 months of cash runway.
What is NeuroOne Medical Technologies Corporation's market capitalization?
NeuroOne Medical Technologies Corporation's market capitalization is approximately $27.9M.
Get the full picture on NeuroOne Medical Technologies Corporation
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.